Literature DB >> 28337276

MicroRNA-9 regulates non-small cell lung cancer cell invasion and migration by targeting eukaryotic translation initiation factor 5A2.

Guodong Xu1, Guofeng Shao2, Qiaoling Pan2, Lebo Sun2, Dawei Zheng2, Minghui Li3, Ni Li2, Huoshun Shi2, Yiming Ni4.   

Abstract

MicroRNAs (miRNAs) play a critical role in cancer development and progression. Bioinformatics analyses has identified eukaryotic translation initiation factor 5A2 (eIF5A2) as a target of miR-9. In this study, we attempted to determine whether miR-9 regulates non-small cell lung cancer (NSCLC) cell invasion and migration by targeting eIF5A2 We examined eIF5A2 expression using reverse transcription-quantitative PCR (RT-qPCR) and subsequently transfected A549 and NCI-H1299 NSCLC cells with a miR-9 mimic or miR-9 inhibitor to determine the migration and invasive capability of the cells via wound healing assay and Transwell invasion assay, respectively. E-cadherin and vimentin expression was detected with western blotting. The miR-9 mimic significantly reduced NSCLC cell invasive and metastatic ability, and the miR-9 inhibitor enhanced NSCLC cell migration activity, increasing the number of migrated cells. There was no significant difference between the negative control siRNA and miR-9 mimic groups after knockdown of eIF5A2; western blotting showed that miR-9 regulated E-cadherin and vimentin expression. These data show that miR-9 regulates NSCLC cell invasion and migration through regulating eIF5A2 expression. Taken together, our findings suggest that the mechanism of miR-9-regulated NSCLC cell invasion and migration may be related to epithelial-mesenchymal transition.

Entities:  

Keywords:  eIF5A2; invasion and migration; microRNA-9; non-small cell lung cancer (NSCLC)

Year:  2017        PMID: 28337276      PMCID: PMC5340683     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  41 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

3.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.

Authors:  Anurag Singh; Patricia Greninger; Daniel Rhodes; Louise Koopman; Sheila Violette; Nabeel Bardeesy; Jeff Settleman
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

4.  Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymaltransition.

Authors:  Wei Zhu; Mu-Yan Cai; Zhu-Ting Tong; Sui-Sui Dong; Shi-Juan Mai; Yi-Ji Liao; Xiu-Wu Bian; Marie C Lin; Hsiang-Fu Kung; Yi-Xin Zeng; Xin-Yuan Guan; Dan Xie
Journal:  Gut       Date:  2011-08-03       Impact factor: 23.059

5.  Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma.

Authors:  Dong-Jiang Tang; Sui-Sui Dong; Ning-Fang Ma; Dan Xie; Leilei Chen; Li Fu; Sze Hang Lau; Yan Li; Yan Li; Xin-Yuan Guan
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

6.  Acquisition of 5-fluorouracil resistance induces epithelial-mesenchymal transitions through the Hedgehog signaling pathway in HCT-8 colon cancer cells.

Authors:  Yanjun Liu; Fangfang DU; Qiannan Zhao; Jian Jin; Xin Ma; Huazhong Li
Journal:  Oncol Lett       Date:  2015-04-23       Impact factor: 2.967

7.  Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients.

Authors:  Li-Ru He; Hong-Yun Zhao; Bin-Kui Li; Yan-Hui Liu; Meng-Zhong Liu; Xin-Yuan Guan; Xiu-Wu Bian; Yi-Xin Zeng; Dan Xie
Journal:  Int J Cancer       Date:  2011-07-01       Impact factor: 7.396

8.  N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of NSCLC cells to cetuximab through inhibition of eukaryotic translation initiation factor 5A2 activation.

Authors:  X Wang; R Jiang; E-H Cui; W-M Feng; H-H Guo; D-H Gu; C-W Tang; T Xue; Y Bao
Journal:  Eur Rev Med Pharmacol Sci       Date:  2016-04       Impact factor: 3.507

9.  Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.

Authors:  Guodong Xu; Hui Yu; Xinbao Shi; Lebo Sun; Qingyun Zhou; Dawei Zheng; Huoshun Shi; Ni Li; Xianning Zhang; Guofeng Shao
Journal:  BMC Pulm Med       Date:  2014-11-07       Impact factor: 3.317

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  19 in total

1.  Evaluation of the relationship between the IL-17A gene expression level and regulatory miRNA-9 in relation to tumor progression in patients with non-small cell lung cancer: a pilot study.

Authors:  Monika Migdalska-Sęk; Katarzyna Góralska; Sławomir Jabłoński; Jacek Kordiak; Ewa Nawrot; Justyna M Kiszałkiewicz; Dorota Pastuszak-Lewandoska; Kamila Baran; Michał Stuss; Ewa Brzeziańska-Lasota
Journal:  Mol Biol Rep       Date:  2019-11-09       Impact factor: 2.316

2.  MicroRNA-598 inhibits the proliferation and invasion of non-small cell lung cancer cells by directly targeting ZEB2.

Authors:  Xiangdong Tong; Peng Su; Haitao Yang; Fusheng Chi; Lin Shen; Xiao Feng; Hongqian Jiang; Xiuchun Zhang; Zhenyuan Wang
Journal:  Exp Ther Med       Date:  2018-10-03       Impact factor: 2.751

Review 3.  Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer.

Authors:  Kentaro Inamura
Journal:  Cancers (Basel)       Date:  2017-05-09       Impact factor: 6.639

4.  HSP90: A Novel Target Gene of miRNA-628-3p in A549 Cells.

Authors:  Jieli Pan; Fusheng Jiang; Jia Zhou; Dehong Wu; Zhenhua Sheng; Meiya Li
Journal:  Biomed Res Int       Date:  2018-05-20       Impact factor: 3.411

5.  MicroRNA-9 Enhanced Cisplatin Sensitivity in Nonsmall Cell Lung Cancer Cells by Regulating Eukaryotic Translation Initiation Factor 5A2.

Authors:  Qiaoling Pan; Lebo Sun; Dawei Zheng; Ni Li; Huoshun Shi; Jie Song; Guofeng Shao; Guodong Xu
Journal:  Biomed Res Int       Date:  2018-08-05       Impact factor: 3.411

6.  Identification and validation of a four-miRNA (miRNA-21-5p, miRNA-9-5p, miR-149-5p, and miRNA-30b-5p) prognosis signature in clear cell renal cell carcinoma.

Authors:  Mingzhi Xie; Yufeng Lv; Zhihui Liu; Jingyan Zhang; Chaoyong Liang; Xiaoli Liao; Rong Liang; Yan Lin; Yongqiang Li
Journal:  Cancer Manag Res       Date:  2018-11-15       Impact factor: 3.989

7.  Eukaryotic translation initiation factor 5A-2 involves in doxorubicin-induced epithelial-mesenchymal transition in oral squamous cell carcinoma cells.

Authors:  Liang Fang; Li Gao; Lei Xie; Guizhou Xiao
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

8.  Effect of midkine on gemcitabine resistance in biliary tract cancer.

Authors:  Yongliang Lu; Bing Yan; Huihui Guo; Li Qiu; Xinrong Sun; Xiang Wang; Qian Shi; Ying Bao
Journal:  Int J Mol Med       Date:  2018-01-18       Impact factor: 4.101

9.  TGF-β1-induced epithelial-mesenchymal transition in lung cancer cells involves upregulation of miR-9 and downregulation of its target, E-cadherin.

Authors:  Hui Wang; Qian Wu; Ying Zhang; Hua-Nan Zhang; Yong-Bin Wang; Wei Wang
Journal:  Cell Mol Biol Lett       Date:  2017-11-02       Impact factor: 5.787

Review 10.  Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers.

Authors:  Ivana Catacchio; Anna Scattone; Nicola Silvestris; Anita Mangia
Journal:  Transl Oncol       Date:  2018-05-03       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.